Aggregate Reporting (PADER/PSUR)
At Masuu Global, we provide comprehensive end-to-end support for aggregate reporting, specializing in the preparation of Periodic Adverse Drug Experience Reports (PADER) and Periodic Safety Update Reports (PSUR). Our services ensure that these reports are accurately prepared, thoroughly analyzed, quality-controlled, and compliant with global regulatory requirements for successful submission and approval.
We understand the critical role of PADER and PSUR in pharmacovigilance and regulatory compliance. By leveraging our expertise, your organization can meet regulatory requirements with precision, ensuring ongoing drug.
Our Aggregate Reporting Process:- PADER/PSUR Preparation
- Complete and Accurate Reporting: Every relevant piece of safety data is included in the reports to provide an accurate overview of the drug’s safety profile.
- Timely and Compliant Submissions: We ensure that reports are prepared in accordance with regulatory deadlines and compliance guidelines, enabling successful and on-time submissions.
- Data Integration
- Individual Case Safety Reports (ICSRs): Extracting and analyzing data from adverse event reports.
- Clinical Trials: Incorporating data from ongoing clinical trials and studies.
- Literature & Post-Marketing Data: Including findings from published medical literature and real-world evidence.
- Generation of Line Listing from the Database
- Data Extraction: Our team generates detailed line listings from the pharmacovigilance database. These line listings summarize individual case safety reports (ICSRs), allowing a clear snapshot of the adverse events.
- Compliance: We ensure the line listings adhere to regulatory standards and guidelines, such as those from the FDA, EMA, and ICH.
- Draft Report Creation
- Initial Drafting: We create an initial draft of the PADER or PSUR, incorporating all integrated data and analyses, with a focus on highlighting critical safety findings, trends, and any emerging safety signals.
- Client Collaboration: We collaborate with our clients to refine and review the draft reports, ensuring that all data and analyses are correctly interpreted and presented. This collaborative approach ensures that the reports reflect both the data and the client’s expectations.
- Medical Analysis and Expert Review
- Expert Review: Our team of medical experts conducts an in-depth analysis of the data, identifying trends, patterns, and potential safety signals that may require further investigation or action.
- Scientific Interpretation: Using our scientific expertise, we interpret clinical data and provide insights to support the overall benefit-risk evaluation of the drug. This helps ensure that the report is clinically sound and accurate in its assessment of drug safety.
- Quality Control (QC) of the Report
- Rigorous QC Checks: We conduct comprehensive quality control (QC) on the draft reports to verify that all data is accurate, complete, and compliant with regulatory standards.
- Error Correction: Any discrepancies, errors, or gaps identified during the QC process are promptly corrected to ensure the highest quality of reporting.
- Final Report Validation: This step ensures that the report is finalized with complete confidence in its accuracy and regulatory compliance.
- Final Client Approval
- Feedback Integration: Any final client feedback or concerns are addressed to guarantee that the report meets the client’s needs and expectations.
- Approval for Submission: Upon approval, the report is ready for submission to regulatory authorities.
- Regulatory Submission
- Timely Submission: Reports are submitted in alignment with the regulatory deadlines, avoiding any delays in compliance.
- Successful Approval: With our rigorous process, we aim to ensure that every report meets regulatory standards and is accepted by health authorities.
Frequently Asked Questions
Aggregate reporting involves periodically collecting, analyzing, and evaluating safety information from multiple sources to assess a medicine’s overall safety profile. Unlike an individual case safety report, which focuses on a single adverse event, aggregate reports provide a broader assessment of safety data and emerging trends.
PADER stands for Periodic Adverse Drug Experience Report. It is a periodic safety report associated with marketed medicines in the United States. PADERs summarize relevant adverse drug experience information and provide regulators with an ongoing assessment of reported safety information following a product’s approval and marketing.
PSUR stands for Periodic Safety Update Report. It is an aggregate safety report that periodically evaluates available safety information for a medicinal product. The assessment can include information from individual safety reports, clinical studies, literature, and post-marketing experience to support continued evaluation of the product’s safety profile.
An ICSR focuses on an individual safety case involving a suspected adverse event, whereas an aggregate safety report evaluates safety information from multiple cases and other sources over a defined period. Aggregate reporting therefore provides a broader assessment of safety trends, emerging signals, and the overall benefit-risk profile.
Aggregate safety reports can integrate information from multiple sources, including Individual Case Safety Reports, clinical trials, scientific literature, observational studies, and post-marketing experience. Combining these sources allows safety teams to evaluate available information collectively rather than assessing adverse events only as separate individual cases.
PADERs and PSURs provide a structured periodic assessment of accumulated safety information. They help identify important safety findings, trends, and potential signals that may require further evaluation. The reports also support regulatory oversight by presenting relevant safety information for assessment of a medicine’s ongoing safety profile.
A line listing is a structured presentation of individual safety cases extracted from a pharmacovigilance database. It provides a summarized view of reported adverse events and relevant case information. In aggregate reporting, line listings can help reviewers examine individual cases alongside broader analyses of cumulative safety data.
Safety signals can be evaluated by analyzing accumulated safety information for patterns, trends, and findings that may warrant further investigation. Aggregate reporting combines data from different sources and includes medical and scientific assessment to identify important safety findings and support the broader evaluation of a product’s benefit-risk profile.
Medical analysis involves reviewing and interpreting accumulated safety information to understand its clinical significance. It can include examining trends, patterns, and potential safety signals within the available data. The analysis contributes to the overall safety assessment and helps determine whether particular findings require additional investigation or regulatory action.
Quality control involves reviewing the report to verify that the information is accurate, complete, consistent, and aligned with applicable regulatory requirements. The process can identify discrepancies, errors, or information gaps before finalization. A final validation step helps ensure that the completed report is suitable for regulatory submission.
Data integration brings safety information from different sources together for a consolidated assessment. Sources may include ICSRs, clinical trials, literature, and post-marketing data. Integrating these datasets allows safety reviewers to examine the available evidence collectively and develop a more complete understanding of the product’s safety profile.
Benefit-risk assessment considers the available evidence about a medicine’s benefits alongside identified or potential risks. In aggregate reporting, accumulated safety information is analyzed to determine whether new findings could affect the product’s overall safety profile. This assessment forms an important part of evaluating ongoing product safety.
PBRER stands for Periodic Benefit-Risk Evaluation Report. It is an aggregate report designed to provide a comprehensive assessment of a medicine’s benefits and risks using available information accumulated over a reporting interval. PBRERs are part of the international pharmacovigilance framework associated with ICH guidance.
DSUR stands for Development Safety Update Report. It is used during clinical development to provide periodic review of safety information from an investigational product’s development program. The report brings together relevant clinical-trial safety information and supports ongoing assessment of the investigational product during development.
Published medical literature can provide additional information about adverse events, safety findings, and emerging concerns associated with a medicinal product. Relevant literature findings can be incorporated into aggregate safety assessments alongside data from clinical trials, individual safety reports, and post-marketing experience to provide a broader evidence base.
Pharmacovigilance databases contain individual safety cases that contribute to cumulative safety analysis. Data extracted from these systems can be reviewed through line listings and other analyses when preparing aggregate reports. Accurate and current database information is therefore important for producing reliable assessments of accumulated safety data.
Preparation generally involves collecting and integrating relevant safety data, generating line listings, analyzing the information, drafting the report, conducting medical review, performing quality-control checks, and incorporating required changes before final approval. The completed report can then be submitted to the applicable regulatory authority within the required timeframe.
Aggregate safety reports are subject to regulatory requirements that can specify reporting periods, formats, and submission deadlines. Meeting the applicable timelines ensures that regulatory authorities receive updated safety information as required. The specific requirements vary according to the regulatory authority, product, reporting type, and applicable pharmacovigilance framework.
Aggregate reporting supports ongoing safety monitoring by bringing together accumulated information from individual cases, clinical studies, literature, and post-marketing experience. Reviewing this information periodically can reveal trends or potential safety signals that may not be apparent from individual reports alone, supporting continued evaluation of the product’s safety profile.
The overall purpose of PADER and PSUR reporting is to provide a structured, periodic evaluation of accumulated safety information for a medicinal product. These reports bring together data from multiple sources, assess important safety findings and potential signals, and support regulatory evaluation of the product’s ongoing safety profile.
